Synlogic (SYBX) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SYBX shares.
View SYBX analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 1-year price objectives for Synlogic's stock. Their SYBX share price forecasts range from $75.00 to $120.00. On average, they anticipate the company's share price to reach $95.00 in the next twelve months. This suggests a possible upside of 3,280.8% from the stock's current price.
View analysts price targets for SYBX or view top-rated stocks among Wall Street analysts.

Synlogic's stock was trading at $11.40 at the beginning of 2023. Since then, SYBX stock has decreased by 75.4% and is now trading at $2.81.
View the best growth stocks for 2023 here.

Synlogic saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 301,400 shares, an increase of 56.7% from the August 31st total of 192,400 shares. Based on an average daily volume of 202,700 shares, the days-to-cover ratio is presently 1.5 days. Approximately 0.7% of the shares of the company are short sold.
View Synlogic's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our SYBX earnings forecast.

Synlogic, Inc. (NASDAQ:SYBX) released its quarterly earnings data on Thursday, August, 10th. The biotechnology company reported ($3.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.90) by $0.75. The biotechnology company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.18 million. Synlogic had a negative net margin of 6,573.82% and a negative trailing twelve-month return on equity of 85.18%.

Synlogic's stock reverse split on Thursday, September 28th 2023. The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM).

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SYBX stock can currently be purchased for approximately $2.81.

Synlogic (NASDAQ:SYBX) has a market capitalization of $12.87 million and generates $1.18 million in revenue each year. The biotechnology company earns $-66,150,000.00 in net income (profit) each year or ($13.9430) on an earnings per share basis.

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The official website for the company is www.synlogictx.com. The biotechnology company can be reached via phone at (617) 401-9975, via email at liz@synlogictx.com, or via fax at 512-681-5201.